A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes

Author:

Tran-Duy An1ORCID,Knight Josh1,Palmer Andrew J.12,Petrie Dennis13,Lung Tom W.C.45,Herman William H.6ORCID,Eliasson Björn78ORCID,Svensson Ann-Marie78,Clarke Philip M.19ORCID

Affiliation:

1. Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia

2. Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

3. Centre for Health Economics, Monash University, Caulfield East, Australia

4. The George Institute for Global Health, University of New South Wales, Sydney, Australia

5. Faculty of Medicine and Health, University of Sydney, Sydney, Australia

6. Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI

7. National Diabetes Register, Centre of Registers, Gothenburg, Sweden

8. Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

9. Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Headington, U.K.

Abstract

OBJECTIVE To develop a patient-level simulation model for predicting lifetime health outcomes of patients with type 1 diabetes and as a tool for economic evaluation of type 1 diabetes treatment based on data from a large, longitudinal cohort. RESEARCH DESIGN AND METHODS Data for model development were obtained from the Swedish National Diabetes Register. We derived parametric proportional hazards models predicting the absolute risk of diabetes complications and death based on a wide range of clinical variables and history of complications. We used linear regression models to predict risk factor progression. Internal validation was performed, estimates of life expectancies for different age-sex strata were computed, and the impact of key risk factors on life expectancy was assessed. RESULTS The study population consisted of 27,841 patients with type 1 diabetes with a mean duration of follow-up of 7 years. Internal validation showed good agreement between the predicted and observed cumulative incidence of death and 10 complications. Simulated life expectancy was ∼13 years lower than that of the sex- and age-matched general population, and patients with type 1 diabetes could expect to live with one or more complications for ∼40% of their remaining life. Sensitivity analysis showed the importance of preventing renal dysfunction, hypoglycemia, and hyperglycemia as well as lowering HbA1c in reducing the risk of complications and death. CONCLUSIONS Our model was able to simulate risk factor progression and event histories that closely match the observed outcomes and to project events occurring over patients’ lifetimes. The model can serve as a tool to estimate the impact of changing clinical risk factors on health outcomes to inform economic evaluations of interventions in type 1 diabetes.

Funder

National Health and Medical Research Council

Australian Research Council’s Discovery Early Career Researcher Awards

Australian Research Council’s Centre of Excellence in Population Ageing Research

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3